Spots Global Cancer Trial Database for Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

Official Title: CCCWFU 99108 - Effect of Exercise Training in Patients Receiving Anthracycline Drugs - A Pilot Study

Study ID: NCT00728429

Conditions

Cardiac Toxicity

Chemotherapeutic Agent Toxicity

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

exercise intervention

Study Description

Brief Summary: RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works in patients receiving chemotherapy for cancer.

Detailed Description: OBJECTIVES: * To determine if patients with cancer can exercise safely and routinely, under supervision, while receiving anthracycline chemotherapy. * To determine the magnitude of the change in the peak ventilatory oxygen uptake (VO2) before and after completion of anthracycline chemotherapy with concurrent exercise versus without exercise in patients with cancer. OUTLINE: Patients are randomized to 1 of 2 intervention arms. * Arm I (exercise): Patients undergo supervised aerobic exercise (walk or bicycle) 3 days a week concurrently with standard anthracycline-based chemotherapy for approximately 18-24 weeks. * Arm II (non-exercise): Patients receive standard anthracycline-based chemotherapy for approximately 18-24 weeks. Patients undergo peak ventilatory oxygen uptake (VO_2) by exercise bike test with gas exchange analysis at baseline and at 2 weeks after completion of anthracycline-based chemotherapy.